PPARgamma agonist19 (Compound 5e) is a PPARgamma agonist with an IC50 of 11.27 µM for COX-1 and 0.05 µM for COX-2. It enhances glucose uptake in rat hemidiaphragm assays more effectively than pioglitazone. Additionally, PPARgamma agonist19 reduces hyperglycemia and insulin resistance in type 2 diabetic rat models and protects against renal and lipid damage caused by metabolic dysfunction.
Target-Kategorie:
PPAR|||COX
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
